Recurrent serous macular detachment after topical ocular hypotensive medication.
We document the recurrence of a CSMD in a patient subsequent to the instillation of topical ocular hypotensive medications and its resolution on discontinuation of therapy. An independent cause or causes contributing to the development of CSMD other than the use of topical ocular hypotensive medications cannot be ruled out in this case, neither can it be considered dissociated from the use of these drugs. We recommend that patients with VTS, those with a history of CSMD or having developed recurrent episodes of CSMD requiring management with topical ocular hypotensive medications, be cautiously monitored for the possible occurrence or exacerbation of CSMD.
Nova Southeastern University College of Optometry, Miami Beach Florida 33162, USA. ebesada@nova.edu
Eulogio
E
Besada
Diana
D
Shechtman
Barry J
BJ
Frauens
D000287:Administration, Topical; D000959:Antihypertensive Agents / Q000009:adverse effects*; D003000:Clonidine / Q000009:adverse effects / Q000031:analogs & derivatives; D004338:Drug Combinations; D004359:Drug Therapy, Combination; D006801:Humans; D007429:Intraocular Pressure / Q000187:drug effects; D008297:Male; D008875:Middle Aged; D009798:Ocular Hypertension / Q000188:drug therapy; D012008:Recurrence; D012163:Retinal Detachment / Q000139:chemically induced* / Q000175:diagnosis; D044967:Serum; D013449:Sulfonamides / Q000009:adverse effects; D013876:Thiophenes / Q000009:adverse effects; D013999:Timolol / Q000009:adverse effects; D041623:Tomography, Optical Coherence; D014792:Visual Acuity
D000959:Antihypertensive Agents; D004338:Drug Combinations; D013449:Sulfonamides; D013876:Thiophenes; C479140:dorzolamide-timolol combination; D013999:Timolol; C016986:apraclonidine; D003000:Clonidine